Beam Therapeutics carries roughly 48% upside to the analyst consensus target, but the investment case is undermined by cash burn equal to 142% of revenue, a pipeline concentrated in a single asset, and a 32% short interest reflecting strong institutional skepticism about the clinical risk/reward.
Thesis pillars
- Pipeline Single Asset Concentration↓Deteriorating
- Analyst Consensus Material Upside→Stable
- High Short Interest Bearish Conviction↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Beam Therapeutics Inc. (BEAM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.27: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 3.06; Below-average business quality.
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies single DNA bases without double-stranded breaks. The lead program, risto-cel, is an autologous hematopoietic stem cell... Read more
Sell if holding. Engine safety override at $24.27: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 3.06; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Beam Therapeutics Inc.
About Beam Therapeutics Inc.
Beam Therapeutics' five clinical-stage programs center on proprietary base editing technology that modifies single DNA bases without double-stranded breaks. Risto-cel, an autologous HSC therapy for sickle cell disease, showed mean HbF levels above 60% in 31 BEACON trial patients through the August 2025 data cut, with BLA submission targeted for year-end 2026. BEAM-302 for alpha-1 antitrypsin deficiency has received FDA alignment on a potential accelerated approval pathway based on AAT biomarkers evaluated over 12 months, with updated Phase 1/2 data expected in Q1 2026.
Beam Therapeutics is pre-revenue, funding operations through equity and debt financing including a facility with Sixth Street Lending Partners. The company operates a 100,000 square foot cGMP manufacturing facility in Research Triangle Park, North Carolina, designed to support ex vivo cell therapy and in vivo LNP programs, supplemented by CMOs with genetic medicine experience for initial clinical trials. The base editing platform creates outbound partnering opportunities, which the company describes as an important element of its business model, allowing it to pursue precision genetic medicine applications beyond its internal focus areas. Risto-cel uses autologous ex vivo base editing via electroporation — the same technology platform used in allogeneic HSC transplantation — while BEAM-302, BEAM-301, and BEAM-304 use lipid nanoparticle in vivo delivery to the liver, a clinically validated modality.
Show full overview
The company's near-term value is substantially concentrated in the risto-cel BLA outcome: adult and adolescent enrollment in the BEACON trial was complete and manufacturing of all doses was completed as of December 2025, with the FDA having granted orphan drug designation and RMAT designation to risto-cel. One patient in the BEACON trial died four months post-infusion from respiratory failure determined to be likely related to busulfan conditioning and unrelated to risto-cel — an adverse event the company disclosed, which illustrates the binary nature of the single pivotal data set. BLA submission timing depends on data maturity from the full 50-patient cohort and FDA review cadence.
See also: Healthcare · Biotechnology
From Beam Therapeutics Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-09-25Recent Developments — Beam Therapeutics Inc.
Latest news
- NEWS Squeeze Watch: 10 Stocks With Over 33% Short Interest — benzinga Sep 25, 2026 neutral
- NEWS Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets — benzinga Sep 22, 2026 neutral
- NEWS These 10 Stocks Are Squeeze Candidates Waiting to Happen — benzinga Sep 14, 2026 neutral
- NEWS Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target — benzinga Sep 9, 2026 positive
- NEWS Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment — benzinga Sep 8, 2026 positive
Generated 2026-09-25T20:52:02Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineristo-cel10-K Item 1: 'We expect to submit a BLA for risto-cel as early as year-end 2026'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -55.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.27: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 39%; Elevated put/call ratio: 3.06; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $22.57. Score 4.3/10, moderate confidence.
Take-profit target: $45.37 (+87.0% upside). Prior stop was $22.57. Stop-loss: $22.57.
Concentration risk — Pipeline: risto-cel; Quality below floor (1.8 < 4.0).
Beam Therapeutics Inc. trades at a P/E of N/A (forward -5.2). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $52.
What does Beam Therapeutics Inc. do?Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary...
Beam Therapeutics is a clinical-stage biotechnology company developing precision genetic medicines using proprietary base editing technology, which modifies single DNA bases without double-stranded breaks. The lead program, risto-cel, is an autologous hematopoietic stem cell therapy for sickle cell disease in a Phase 1/2 trial with BLA submission targeted for year-end 2026; secondary programs include BEAM-302 (alpha-1 antitrypsin deficiency) and BEAM-301 (GSDIa) in Phase 1/2.